logo-loader

Avacta Group PLC

Receive alerts
Market:
AIM
Market Cap:
£39.23 m
Price
22.30 GBX
Change
10.12%
52 weeks high
49.80
52 weeks low
15.00

In brief

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.